Abstract
A NEW step in the rationalization of the British fine chemical industry has been taken by the formation of the Therapeutic Research Corporation of Great Britain, Ltd., the directors of which are Lord Trent, of Boots Pure Drug Company, Ltd., Mr. C. A. Hill, of the British Drug Houses, Ltd., Mr. H. Jephcott, of Glaxo Laboratories, Ltd., Mr. T. B. Maxwell, of May and Baker, Ltd., and Mr. T. R. G. Bennett, of the Wellcome Foundation, Ltd. Although each of the directors of the new Corporation is managing director of his own concern, the Corporation is not an amalgamation of these five firms. Each will retain its freedom of action in its special field, but will contribute to the common research pool; in effect, a much extended research team now becomes available for work on new drugs, and overlapping effort should be eliminated. It is also hoped to secure the interest and co–operation of research workers in academic institutions. The Corporation will have in the various chemical, physiological and bacteriological laboratories at its command the choice of many different lines of approach to its problems and the call on the extensive scientific personnel and equipment of the five companies which are collaborating. This should make for a hopeful start and lay the foundation of a promising superstructure.
Article PDF
Rights and permissions
About this article
Cite this article
Therapeutic Research Corporation. Nature 148, 658 (1941). https://doi.org/10.1038/148658b0
Issue Date:
DOI: https://doi.org/10.1038/148658b0